


Antitumor agent-138

Cat. No.:	HY-162227
CAS No.:	2975168-22-8
Molecular Formula:	C ₂₀ H ₂₁ N ₃ O ₄
Molecular Weight:	367.4
Target:	Microtubule/Tubulin; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antitumor agent-138 (compound 5b) is an inhibitor against tubulin polymerization at tubulin colchicine-binding sites, with IC ₅₀ of 1.87 μM. Antitumor agent-138 arrests the cell cycle at G2/M phase and induces an apoptosis in MCF-7 cells. Antitumor agent-138 inhibits cells migration and angiogenesis ^[1] .																		
In Vitro	<p>Antitumor agent-138 exhibits anti-proliferative properties in cells MCF-7, A549, MDA-MB-231, HT-29, HeLa and L02, with IC₅₀s of 0.04, 0.39, 0.04, 0.06, 0.11 and 2.73 μM, respectively^[1].</p> <p>Antitumor agent-138 (5-20 nM) inhibits the colony formation in human breast cancer cells MCF-7^[1].</p> <p>Antitumor agent-138 (25-200 nM) induces microtubule collapse in MCF-7 cells^[1].</p> <p>Antitumor agent-138 (6.25-50 nM) inhibits the HUVEC tubes formation in a dose-dependent manner and exhibits an anti-vascular activity^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Migration Assay ^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549</td> </tr> <tr> <td>Concentration:</td> <td>6.25-50 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited the cell migration in a dose-dependent manner.</td> </tr> </table> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7, A549, MDA-MB-231, HT-29, HeLa and L02</td> </tr> <tr> <td>Concentration:</td> <td>0-5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Exhibited anti-proliferative properties in cancer cells MCF-7, A549, MDA-MB-231, HT-29, HeLa with low concentrations in nanomole.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7</td> </tr> </table>	Cell Line:	A549	Concentration:	6.25-50 nM	Incubation Time:	24 h	Result:	Inhibited the cell migration in a dose-dependent manner.	Cell Line:	MCF-7, A549, MDA-MB-231, HT-29, HeLa and L02	Concentration:	0-5 μM	Incubation Time:	48 h	Result:	Exhibited anti-proliferative properties in cancer cells MCF-7, A549, MDA-MB-231, HT-29, HeLa with low concentrations in nanomole.	Cell Line:	MCF-7
Cell Line:	A549																		
Concentration:	6.25-50 nM																		
Incubation Time:	24 h																		
Result:	Inhibited the cell migration in a dose-dependent manner.																		
Cell Line:	MCF-7, A549, MDA-MB-231, HT-29, HeLa and L02																		
Concentration:	0-5 μM																		
Incubation Time:	48 h																		
Result:	Exhibited anti-proliferative properties in cancer cells MCF-7, A549, MDA-MB-231, HT-29, HeLa with low concentrations in nanomole.																		
Cell Line:	MCF-7																		

	Concentration:	6.25-25 nM
	Incubation Time:	24 h
	Result:	Increased P21, Cyclin B1, Cdc25c and cdk7 in a dose- and time-dependent manner. Increased Bax, Cleaved-PARP, Bim and Cleaved Caspase-9, decreased Bcl-2 in a dose- and time-dependent manner.
	Immunofluorescence ^[1]	
	Cell Line:	MCF-7
	Concentration:	25-200 nM
	Incubation Time:	8 h
	Result:	Disrupted the microtubule network into punctate.
In Vivo	Antitumor agent-138 (20 mg/kg, i.p., 21 days) exhibits an antitumor activity with a tumor growth inhibition rate of 68.95% in MCF-7 xenograft BALB/c nude mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	MCF-7 xenograft in BALB/c nude mice ^[1]
	Dosage:	20 mg/kg
	Administration:	intraperitoneal injection for 21 days
	Result:	Inhibited the tumor growth with TGI of 68.95%

REFERENCES

[1]. Yang Y, et al., Design and synthesis of novel 3-amino-5-phenylpyrazole derivatives as tubulin polymerization inhibitors targeting the colchicine-binding site. Eur J Med Chem. 2024 Jan 24;267:116177.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA